Antibody-drug conjugate design and mechanisms of action for cancer treatment: state of the art and beyond - PubMed
7 hours ago
- #precision-medicine
- #antibody-drug-conjugate
- #cancer-treatment
- Antibody-drug conjugates (ADCs) combine tumor-specific antibodies with toxic payloads to target cancer cells.
- Over 430 ADCs have reached clinical trials in the past two decades, with 14 FDA-approved for oncology.
- Advances in antibody technology and conjugation methods improve precision and effectiveness of ADCs.
- Emerging trends include new antigen targets, linker chemistry, payloads, and combination with immunotherapy.
- AI and biomarker discovery are shaping the future of ADC development for personalized cancer treatments.
- The review highlights the evolution, characteristics, and future directions in ADC design.